Health Technology Appraisal: trastuzumab
and vinorelbine for breast cancer
CHANGES TO THE APPRAISAL SCHEDULE
As you are aware, we have received instructions
from the Appraisal Committee that they wish to consider additional
clinical data available for these technologies. The Institute
has been in dialogue with the National coordinating centre for
Health Technology Assessment and the University of York to commission
this additional review.
Assessment of manufacturers submissions and
preliminary literature searches undertaken by the York rapid review
team has revealed a large body of non-randomised clinical data
for vinorelbine and a smaller data set for trastuzumab. As a consequence
the Institute has decided to separate the appraisal of these technologies.
The Appraisal Committee will review additional data for trastuzumab
at its meeting on the 25 October 2001 and will review additional
data for vinorelbine at its meeting on the 21 March 2002.
Further details of new timings for the appraisal
of these technologies will be available from our website, www.nice.org.uk,
within the next few days.
Appraisal Programme Director